Treatment of ocular hypertension with a synergistic combination for ocular administration
AssigneeR-Tech Ueno, Ltd.
InventorRyuji Ueno
Life of this patent
Estimating the term…
Abstract
A method for treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of (a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and (b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in an amount effective in treatment of ocular hypertension.
Claims11
A method for treatment of ocular hypertension which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of
- (a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and
- (b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in an amount effective in treatment of ocular hypertension.
A pharmaceutical composition for treatment of ocular hypertension by ocular administration thereof comprising an oculo-hypotensively synergistic combination of
- (a) a 13,14-dihydro-15-keto-20-loweralkylprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and
- (b) a polyoxyethylenesorbitan unsaturated higher aliphatic acid monoester in association with a pharmaceutically acceptable carrier, diluent or excipient.
Dependencies are inferred from the claim text.